Cognitive Impairment and Electroconvulsive Therapy in Geriatric Depression, What Could Be the Role of Rivastigmine? A Case Series

Cognitive Impairment and Electroconvulsive Therapy in Geriatric Depression, What Could Be the Role of Rivastigmine? A Case Series

Electroconvulsive therapy (ECT), albeit highly effective in treating depression, is frequently associated with cognitive impairment, either temporary or more persistent. Especially in older patients, who generally respond even better, serious cognitive impairment during the course of ECT may lead to...

Full description

Saved in:
Bibliographic Details
Published in:Clinics and practice Vol. 5; no. 3; p. 780
Main Authors: van Schaik, Audrey Monica, Rhebergen, Didi, Henstra, Marieke Jantien, Kadouch, Daniel J., van Exel, Eric, Stek, Maximilianus Lourentius
Format: Journal Article
Language:English
Published: PAGEPress Publications, Pavia, Italy 28-09-2015
MDPI AG
Subjects:
acetylcholinesterase inhibitor
Case Report
cognitive impairment
Depression
elderly
electroconvulsive therapy
rivastigmine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Electroconvulsive therapy (ECT), albeit highly effective in treating depression, is frequently associated with cognitive impairment, either temporary or more persistent. Especially in older patients, who generally respond even better, serious cognitive impairment during the course of ECT may lead to premature termination of ECT. Treatment of this cognitive impairment is of utmost importance. In this case series report, we present the effect of rivastigmine, an acetylcholinesterase inhibitor, on cognitive impairment in three older, severely depressed patients during or after a course of ECT. An improvement of cognitive functioning, in particular a decline of confusional symptoms, was observed in two patients with structural brain alterations associated with aging. In the other patient, who suffered primarily from amnesia, no effect of rivastigmine was observed. These preliminary results emphasize the need for detailed profiling of cognitive impairment when developing a research design to study the potential benefits of rivastigmine in the prevention or treatment of cognitive impairment in severely depressed patients treated with ECT.
Bibliography:Conflict of interest: the authors declare no potential conflict of interest.
ISSN:2039-7283
2039-7275
2039-7283
DOI:10.4081/cp.2015.780